Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$0.51 - $0.78 $153,006 - $234,010
-300,013 Reduced 14.04%
1,837,424 $1.1 Million
Q4 2022

Feb 09, 2023

BUY
$0.47 - $17.22 $1 Million - $36.8 Million
2,136,297 Added 187394.47%
2,137,437 $1.18 Million
Q3 2022

Nov 10, 2022

SELL
$0.74 - $15.01 $852 - $17,291
-1,152 Reduced 50.26%
1,140 $1,000
Q2 2022

Aug 10, 2022

SELL
$0.71 - $2.43 $3,612 - $12,363
-5,088 Reduced 68.94%
2,292 $2,000
Q1 2022

May 12, 2022

SELL
$2.31 - $5.13 $1.06 Million - $2.36 Million
-460,325 Reduced 98.42%
7,380 $18,000
Q4 2021

Feb 10, 2022

BUY
$4.45 - $8.09 $1.05 Million - $1.9 Million
235,390 Added 101.32%
467,705 $2.23 Million
Q3 2021

Nov 10, 2021

BUY
$6.94 - $8.85 $1.61 Million - $2.06 Million
232,315 New
232,315 $1.82 Million

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $409M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.